Sirnaomic
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development 2024-10-04 13:03
Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology 2024-09-19 17:28
Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine 2024-08-01 11:26
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases 2024-07-12 16:53
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics 2024-07-08 14:30
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients 2024-06-28 13:44
Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy 2024-06-13 18:03
Sirnaomics Announces 2023 Annual Results 2024-03-28 17:09
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors 2024-01-24 17:49
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770 2023-12-18 22:04
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment 2023-12-06 01:01
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer 2023-12-01 14:41
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction 2023-11-01 22:07
Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors 2023-08-31 11:30
Sirnaomics Announces 2023 Interim Results 2023-08-31 10:40
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development 2023-07-28 11:56
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences 2023-07-12 20:45
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company 2023-07-05 23:07
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development 2023-06-19 21:29
Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences 2023-06-14 00:42
1 2 3